NCT02305264View on ClinicalTrials.gov

Imaging of Intracerebral Inflammation in MS

NACompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

March 19, 2012

Primary Completion Date

September 10, 2018

Study Completion Date

September 10, 2018

Conditions
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Interventions
DRUG

18F-DPA-714 and 18F-FDG

"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.~18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."

Trial Locations (2)

75012

Saint Antoine Hospital, Paris

75013

Pitie Salpetriere Hospital, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02305264 - Imaging of Intracerebral Inflammation in MS | Biotech Hunter | Biotech Hunter